The new report reveals that many of the authors and reviewers have been outspoken critics of gender-affirming care and belong ...

Pfizer and Tris Pharma agreed to pay $41.5 million to settle allegations they altered testing methods to ensure their ADHD ...

Function Health, a provider of lab testing and other services, announced on Wednesday $298 million in new funding with plans ...

The liability, safety, and accuracy questions underlying one creative proposal, in this week's AI Prognosis newsletter.

Novo Nordisk is set to soon unveil pivotal Phase 3 data on whether semaglutide — the blockbuster GLP-1 drug behind Ozempic ...

Novo Nordisk will soon announce the results of perhaps the most ambitious studies yet of its GLP-1 drug: whether it can help ...

Agios reported mixed results from a Phase 3 study of its drug Pyrukynd in sickle cell, raising doubts about the drug's ...

Novo Nordisk is expected to announce soon whether its blockbuster GLP-1 drug semaglutide can help slow Alzheimer’s disease ...

WASHINGTON — Prospects are not looking good for an extension of the extra tax credits that have helped more Americans buy insurance plans in the Affordable Care Act’s marketplaces. Republicans don’t ...

The first randomized controlled trial of the "California sober" approach suggests marijuana may indeed lessen alcohol ...

A unique Harvard program trains future physicians to recognize structural failures embedded within our health care system.

In a first-of-its-kind randomized trial, people who smoked weed consumed less alcohol in the two hours afterward than those ...